Physiologically Based Pharmacokinetic Modeling of Valemetostat to Inform Dose Recommendations When Coadministered With CYP3A /P‐gp Modulators

Documenti analoghi

• Effect of Rifampicin on the Pharmacokinetics of Valemetostat and Its Primary Metabolite: A Phase 1 Study in Healthy Participants
  di: Masaya Tachibana, et al.
  Pubblicazione: (2025)
• Concentration–QTc Analysis of Valemetostat in Patients With Hematologic Malignancies
  di: Masaya Tachibana, et al.
  Pubblicazione: (2025)
• Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug–Drug Interaction Study in Patients With Non‐Hodgkin Lymphoma
  di: Masaya Tachibana, et al.
  Pubblicazione: (2025)
• A phase I drug–drug interaction study to assess the effect of futibatinib on P‐gp and BCRP substrates and of P‐gp inhibition on the pharmacokinetics of futibatinib
  di: Amanda Long, et al.
  Pubblicazione: (2024)
• Association of Metabolic Genotype Composite CYP3A5*3 and CYP3A4*1B to Tacrolimus Pharmacokinetics in Stable Black and White Kidney Transplant Recipients
  di: Daniel Brazeau, et al.
  Pubblicazione: (2025)